Pulmonary Drug Delivery Systems Market Size to Touch $ 92.4 Bn By 2030

The pulmonary drug delivery system market size was valued approximately at US$ 51.87 billion in 2021 and is projected to reach US$ 92.4 billion by 2030, registering a CAGR of 6.6%.

The base year for the study has been considered 2021, the historic year 2017 and 2020, the forecast period considered is from 2022 to 2030. The pulmonary drug delivery system market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).

Download a FREE Sample Copy (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/

The global pulmonary drug delivery systems market is primarily driven by the rising prevalence of various pulmonary diseases such as asthma, chronic pulmonary obstructive disease, and allergic rhinitis. The increased awareness among the population regarding the control and management of the pulmonary diseases is fueling the demand for the pulmonary drug delivery systems across the globe. The rising pollution levels due to rapid industrialization, rapid urbanization, increased prevalence of smoking, and changing lifestyles is resulting in the growing number of patients suffering from different pulmonary diseases.

According to the World Health Organization, around 90% of the people breathe pollutant air and around 7 million people die every year due to indoor and outdoor pollution. Moreover, the presence of various key market players and their innovative product launches is impacting the increasing demand for the pulmonary drug delivery devices. For instance, in April 2019, Glenmark Pharmaceuticals Ltd. introduced to latest inhalers – one metered dosed inhale named Soprobec and another breathe actuated inhaler named Stalpex.

Scope of the Pulmonary Drug Delivery Systems Market

Pulmonary Drug Delivery Systems Market Report Highlights

• Based on the product, the metered dose inhaler segment dominated the market in 2020. The higher product acceptance and increasing prevalence of pulmonary diseases has fueled the growth of this segment. Moreover, the innovative product launches has further boosted the market growth.
• Based on the indication, asthma accounted for the largest market share in 2020. According to the WHO, asthma affects both the adults and children. Changing lifestyle, rapid urbanization, and extended exposure to harmful particles in air are the major reasons behind the increased prevalence of asthma. The higher demand for the pulmonary drug delivery systems for the treatment of asthma has augmented the growth of this segment.
• Based on the distribution channel, the e-commerce is estimated to be the most opportunistic segment during the forecast period. This is attributable to the increasing penetration of the online pharmacies due to the rising adoption of the smartphones and internet across the globe.

Pulmonary Drug Delivery Systems Market Dynamics

Driver

Rise in the prevalence of pulmonary diseases

According to the World Health Organization, around 65 million people across the globe suffers from COPD and around 3 million dies due to it every year. Around 334 million people are suffering from asthma and around 14% of the global children are affected from it. The rising mortality rates and increased awareness regarding the pulmonary diseases is expected to drive the market growth during the forecast period.

Restraint

Stringent government regulations

The strict regulatory scenario and the regulatory requirements of the drug delivery systems is presenting a challenge to the market players because the pulmonary drug delivery systems are a combination of drug and device. Therefore, it is regulated under new provisions by the government.

Read Also: Energy Storage Systems Market Value to Hit US$ 435 Bn By 2030

Opportunity

New product launches

Philips launched a potable mesh nebulizer named InnoSpire Go in 2018. It is a portable, hand-held, and small-sized, and light-weight nebulizer that can administer drugs in just few minutes. Further, Lupin introduced Adhero in 2019. It is a device that tracks the usage pattern of the metered dose inhalers by the COPD patients. Therefore, the frequent product launches with new and innovative features is expected to drive the growth in the future.

Challenge

Lack of access to the healthcare facilities

There is a lack of adequate healthcare infrastructure and lack of access to basic health facilities in the developing and the underdeveloped markets. Most of the people remain undiagnosed and untreated, which may hamper the market growth.

Regional Snapshot

North America dominated the global pulmonary drug delivery systems market in 2020. This is attributed to the increased demand for the pulmonary drug delivery devices owing to the increasing prevalence of various pulmonary diseases. As per the Asthma and Allergy Foundation of America, around 25 million people were suffering from asthma in 2018 in US. Moreover, as per the American Lung Association, around 16.4 million people in US were diagnosed with some type of COPD such as emphysema, chronic bronchitis, and COPD. The increased healthcare expenditure, higher penetration of pharmacies, and better access to the healthcare facilities are the major factors that drives the demand for the pulmonary drug delivery systems in North America.

Asia Pacific is expected to be the fastest-growing market during the forecast period. This is attributed to the increasing air pollution levels in the region. Moreover, the changing lifestyle of the consumers and rapid industrialization is resulting in an alarming rise in the prevalence of the respiratory and pulmonary diseases. According to the World Health Organization, around 80% of the death due to COPD occurs in the low and middle income countries. Therefore, the presence of huge population and rising mortality rates is expected to drive the market growth in Asia Pacific.

Some of the prominent players in the global pulmonary drug delivery systems market include:

• Philips Respironics
• GlaxoSmithKline PLC
• BoehringerIngelheim GmbH
• TevaPharmaceutical Industries Ltd.
• 3M Healthcare
• PARI GmbH
• F. Hoffmann-La Roche AG
• Gilbert Technologies
• AstraZeneca PLC
• Omron Healthcare, Inc.

Segments Covered in the Report

By Product

• Dry Powder Inhalers
• Nebulizers
• Metered Dose Inhalers
• Accessories

By Indication

• COPD
• Asthma
• Cystic Fibrosis
• Allergic Rhinitis
• Others

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pulmonary Drug Delivery Systems Market 

5.1. COVID-19 Landscape: Pulmonary Drug Delivery Systems Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pulmonary Drug Delivery Systems Market, By Product

8.1. Pulmonary Drug Delivery Systems Market, by Product Type, 2021-2030

8.1.1. Dry Powder Inhalers

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Nebulizers

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Metered Dose Inhalers

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Accessories

8.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Pulmonary Drug Delivery Systems Market, By Indication

9.1. Pulmonary Drug Delivery Systems Market, by Indication, 2021-2030

9.1.1. COPD

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Asthma

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Cystic Fibrosis

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Allergic Rhinitis

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel 

10.1. Pulmonary Drug Delivery Systems Market, by Distribution Channel, 2021-2030

10.1.1. Retail Pharmacy

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Hospital Pharmacy

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. E-Commerce

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Pulmonary Drug Delivery Systems Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2019-2030)

11.1.2. Market Revenue and Forecast, by Indication (2019-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Indication (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Indication (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.2. Market Revenue and Forecast, by Indication (2019-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Indication (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Indication (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Indication (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Indication (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.2. Market Revenue and Forecast, by Indication (2019-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Indication (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Indication (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Indication (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Indication (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.2. Market Revenue and Forecast, by Indication (2019-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Indication (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Indication (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Indication (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Indication (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.5.2. Market Revenue and Forecast, by Indication (2019-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Indication (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Indication (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

Chapter 12. Company Profiles

12.1. Philips Respironics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GlaxoSmithKline PLC

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. BoehringerIngelheim GmbH

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. TevaPharmaceutical Industries Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. 3M Healthcare

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. PARI GmbH

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. F. Hoffmann-La Roche AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Gilbert Technologies

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AstraZeneca PLC

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Omron Healthcare, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Why Buy this Report?

The purpose of Precedence Research’s pulmonary drug delivery system market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com